- Home
- APRE vs ABP Comparison
APRE vs ABP Comparison
Compare APRE & ABP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APRE
- ABP
- Stock Information
- Founded
- APRE 2006
- ABP 2004
- Country
- APRE United States
- ABP United States
- Employees
- APRE N/A
- ABP N/A
- Industry
- APRE Biotechnology: Biological Products (No Diagnostic Substances)
- ABP Biotechnology: Pharmaceutical Preparations
- Sector
- APRE Health Care
- ABP Health Care
- Exchange
- APRE Nasdaq
- ABP Nasdaq
- Market Cap
- APRE 13.5M
- ABP 14.3M
- IPO Year
- APRE 2019
- ABP N/A
- Fundamental
- Price
- APRE $1.50
- ABP $0.32
- Analyst Decision
- APRE Strong Buy
- ABP Strong Buy
- Analyst Count
- APRE 2
- ABP 1
- Target Price
- APRE $15.50
- ABP $4.00
- AVG Volume (30 Days)
- APRE 29.2K
- ABP 184.6K
- Earning Date
- APRE 05-13-2025
- ABP 05-18-2025
- Dividend Yield
- APRE N/A
- ABP N/A
- EPS Growth
- APRE N/A
- ABP N/A
- EPS
- APRE N/A
- ABP N/A
- Revenue
- APRE $1,502,581.00
- ABP $183,000.00
- Revenue This Year
- APRE N/A
- ABP N/A
- Revenue Next Year
- APRE N/A
- ABP N/A
- P/E Ratio
- APRE N/A
- ABP N/A
- Revenue Growth
- APRE 157.63
- ABP 50.00
- 52 Week Low
- APRE $1.41
- ABP $0.23
- 52 Week High
- APRE $5.90
- ABP $13.00
- Technical
- Relative Strength Index (RSI)
- APRE 27.07
- ABP N/A
- Support Level
- APRE $1.41
- ABP N/A
- Resistance Level
- APRE $1.59
- ABP N/A
- Average True Range (ATR)
- APRE 0.11
- ABP 0.00
- MACD
- APRE 0.02
- ABP 0.00
- Stochastic Oscillator
- APRE 18.60
- ABP 0.00
About APRE Aprea Therapeutics Inc. Common stock
Aprea Therapeutics Inc is a clinical-stage biopharmaceutical company. The group is focused on precision oncology through synthetic lethality. Its pipeline product is ATRN-119, a clinical-stage small molecule ATR inhibitor in development for solid tumor indications. APR-1051, an oral, small-molecule WEE1 inhibitor, recently entered the clinic.
About ABP Abpro Holdings Inc Common Stock
Abpro Holdings Inc is a biotechnology company dedicated to developing next-generation antibody therapeutics with the goal of improving the lives of patients with severe and life-threatening diseases. It is focused on novel antibody constructs for immuno-oncology and ophthalmology. By leveraging its proprietary DiversImmune and MultiMabTM antibody discovery and engineering platforms, The company is developing a pipeline of next-generation antibodies, both independently and through collaborations with global pharmaceutical and research institutions.